Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

02 Nov 2016

• By Joseph Haas

Related Content

Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII

25 Sep 2014

Gilead Gets CHMP Nod for New HIV Combo

29 Apr 2016

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

02 Nov 2016

CHMP Positive On Descovy, A Safer HIV Therapy?

28 Feb 2016

With Parity Pricing, Gilead Relies On <em>Genvoya</em> Safety To Convert From <em>Stribild</em>

06 Nov 2015

Gilead: Three HIV Launches Expected In Near-Term Future

28 Oct 2015

Related Companies

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Additional Topics

Launches Business Strategies Sales & Earnings Advertising, Marketing & Sales Commercial Infectious Diseases BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.